NEW ASSAYS FOR PATHOGENS RELEVANT TO BLOOD TRANSFUSION

Information

  • Research Project
  • 2231469
  • ApplicationId
    2231469
  • Core Project Number
    R43HL053509
  • Full Project Number
    1R43HL053509-01
  • Serial Number
    53509
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1994 - 30 years ago
  • Project End Date
    6/29/1995 - 29 years ago
  • Program Officer Name
  • Budget Start Date
    9/30/1994 - 30 years ago
  • Budget End Date
    6/29/1995 - 29 years ago
  • Fiscal Year
    1994
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/15/1994 - 30 years ago
Organizations

NEW ASSAYS FOR PATHOGENS RELEVANT TO BLOOD TRANSFUSION

The strategy for highly parallelized screening of blood borne pathogens is proposed. Constituent steps are simultaneous collection of all suspect pathogens on magnetic beads coated with corresponding antibodies. The polymerase chain reaction (PCR) is then used to amplify different length, targeted segments of the proposed pathogens genomes. The primers carry PG and/or EC isotopic labels incorporated. The 5' (non-priming) end of the primers utilized has an additional Tag sequence with is a source identifier of the donor/patient. Pools of PCR products from different sources are pooled for subsequent analytical steps. A part of each pool of forty is put through the protocol for Direct Sequencing (DS) of genomes of a few megabase complexity. Undegraded PCR fragments are size markers added back to it. After a subsequent size fractionation, the presence of a PCR band corresponding in size to a genome segment of the pathogens is revealed by the high sensitivity MultiPhoton Detector (MPD) used to quantify PG and EC isotopes. MPD allows simultaneous but individual quantitation of multiple co-resident EC and PG labels. Whenever a suspect band is identified, the established DS protocols can be implemented to verity that the PCR band in fact encodes the pathogens sequence. An oligonucleotide probing with specific for the source Tag then identifies the donor/patient carrying the pathogen. The constituent steps have all been performed in other R&D. The two most critical features to be validated in this Phase I with non-hazardous biologicals are the degree of any artifact limitations during the PCR applications and dynamic range limitations during the readout of the fractionated DNAs.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    839
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG7
  • Study Section Name
  • Organization Name
    BIOTRACES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    HERNDON
  • Organization State
    VA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    20171
  • Organization District
    UNITED STATES